BioRestorative Therapies, Inc. (BRTX)
1.54
+0.08
(+5.48%)
USD |
NASDAQ |
Oct 16, 16:00
1.52
-0.02
(-1.30%)
After-Hours: 20:00
BioRestorative Therapies Research and Development Expense (Annual) : 10.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 10.09M |
| December 31, 2024 | 5.349M |
| December 31, 2023 | 4.035M |
| December 31, 2022 | 3.513M |
| December 31, 2021 | 0.7291M |
| December 31, 2020 | 0.8768M |
| December 31, 2019 | 1.722M |
| December 31, 2018 | 1.513M |
| December 31, 2017 | 2.152M |
| Date | Value |
|---|---|
| December 31, 2016 | 2.884M |
| December 31, 2015 | 2.105M |
| December 31, 2014 | 1.431M |
| December 31, 2013 | 1.594M |
| December 31, 2012 | 0.4162M |
| December 31, 2011 | 0.012M |
| December 31, 2010 | 0.0116M |
| December 31, 2009 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Myriad Genetics, Inc. | 106.80M |
| CareDx, Inc. | 71.43M |
| Natera, Inc. | 624.11M |
| Exagen, Inc. | 6.254M |
| Sera Prognostics, Inc. | 12.35M |